Vivos Therapeutics Book Value Per Share Growth & History (VVOS)
Vivos Therapeutics's book value per share was -$0.16 for fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.16 | -$1.51 | — |
| 2024 | 2024-12-31 | $1.35 | $1.13 | +502.61% |
| 2023 | 2023-12-31 | $0.22 | -$4.99 | −95.70% |
| 2022 | 2022-12-31 | $5.22 | -$22.53 | −81.20% |
| 2021 | 2021-12-31 | $27.75 | $4.52 | +19.46% |
| 2020 | 2020-12-31 | $23.23 | $29.14 | — |
| 2019 | 2019-12-31 | -$5.91 | — | — |
Vivos Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.34 | -$0.96 | — |
| Q1 2026 | 2026-03-31 | -$0.08 | -$0.83 | — |
| Q4 2025 | 2025-12-31 | -$0.16 | -$1.51 | — |
| Q3 2025 | 2025-09-30 | $0.31 | -$1.30 | −80.96% |
| Q2 2025 | 2025-06-30 | $0.63 | -$1.24 | −66.47% |
| Q1 2025 | 2025-03-31 | $0.75 | $0.54 | +251.16% |
| Q4 2024 | 2024-12-31 | $1.35 | $1.13 | +502.61% |
| Q3 2024 | 2024-09-30 | $1.61 | $1.57 | +4086.51% |
| Q2 2024 | 2024-06-30 | $1.87 | $0.11 | +6.07% |
| Q1 2024 | 2024-03-31 | $0.21 | -$5.63 | −96.35% |
| Q4 2023 | 2023-12-31 | $0.22 | -$4.99 | −95.70% |
| Q3 2023 | 2023-09-30 | $0.04 | -$10.67 | −99.64% |
| Q2 2023 | 2023-06-30 | $1.76 | -$14.36 | −89.09% |
| Q1 2023 | 2023-03-31 | $5.84 | -$17.02 | −74.44% |
| Q4 2022 | 2022-12-31 | $5.22 | -$22.53 | −81.20% |
| Q3 2022 | 2022-09-30 | $10.71 | -$24.57 | −69.65% |
| Q2 2022 | 2022-06-30 | $16.12 | -$23.86 | −59.68% |
| Q1 2022 | 2022-03-31 | $22.86 | -$8.71 | −27.60% |
| Q4 2021 | 2021-12-31 | $27.75 | $4.52 | +19.46% |
| Q3 2021 | 2021-09-30 | $35.27 | — | — |
| Q2 2021 | 2021-06-30 | $39.98 | — | — |
| Q1 2021 | 2021-03-31 | $31.57 | — | — |
| Q4 2020 | 2020-12-31 | $23.23 | $29.14 | — |
| Q4 2019 | 2019-12-31 | -$5.91 | — | — |
Vivos Therapeutics book value per share trends
Over the last five fiscal years, Vivos Therapeutics's book value per share decreased from $23.23 to -$0.16, a change of -$23.39. The latest reported quarter, Q2 2026, shows -$0.34.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗